Exploiting the “dark matter” of the genome to defeat melanoma KU Leuven
The 5-year survival rates of patients with metastatic melanoma are still about 30%. The major reason for the low survival rate of melanoma patients is intrinsic and acquired resistance to the existing therapies. It is therefore essential to develop new therapeutic strategies that will help eradicating resistant cells. By single-cell RNA sequencing of BRAF mutant patient-derived xenograft (PDX) melanoma models analysis we obtained the lncRNA ...